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DOI 10.1016/j.stem.2011.05.010We read with interest the article by Mai X.
Luong and colleagues illustrating useful
recommendations for a new nomencla-
ture for human embryonic stem cell
(ESC) and induced pluripotent stem cell
(iPSC) lines (Luong et al., 2011). We agree
with the general approach suggested
in the manuscript. We do need a stan-
dardized nomenclature system for ESCs
and iPSCs that aims to avoid the many
problems that might arise due to duplica-
tion and confusion surrounding current
and future names for what promises to
be a virtually limitless number of iPSC
lines.
The proposed approach would assign
a unique ID for each clone by a consistent
and sustainable nomenclature. However,
we believe that the ideal nomenclature
system should be something that reflects
the historical practices within those labo-
ratories that have produced a large
number of ESCs and iPSCs, and yet also
one that can easily and practically be
adopted for future derivations. From this
viewpoint, here, we need to consider at
least two points.
First, the newly assigned clone IDs
should represent the original IDs, espe-
cially for those lines that have been widely
distributed among the global stem cell
community. However, we may have
some problems if we obey the proposed
rule as it stands. For example, the original
iPSC lines established in the Yamanaka
lab were named with IDs like ‘‘201B7’’
(Takahashi et al., 2007). ‘‘201’’ indicates
an experimental number and ‘‘B7’’ repre-
sents a clone name. Although our original
ID consists of five letters and exceeds the
proposed upper limit of four, we prefer to
use the original name, ‘‘CiRA201B7i-WT,’’
for our clone 201B7. These clones have
been distributed worldwide using the
original IDs. In the Daley lab, human
iPSC lines were named according to their606 Cell Stem Cell 8, June 3, 2011 ª2011 Elsdonor cell type, while maintaining the
iPS identifier and a clone number (e.g.,
hFIB2-iPS2; Park et al., 2008). In histor-
ical cases, we recommend retaining the
original clone ID and name instead of
the sequential numbers (yellow box in
Figure 1 of Luong et al., 2011). Alterna-
tively, an optional A-box (for alias) could
be added to the code of a renamed cell
line (e.g., .-A-CiRA201B7i-WT). For
widely distributed lines, maintaining the
original ID or name will allow scientists
immediate recognition and provide
useful historical information on the original
clones and/or references, and thus largely
facilitate the acceptance of such a uniform
labeling system by the scientific commu-
nity. In short, we would recommend
that the proposed rules retain flexibility
for preserving the original clone ID,
which has been already published and
recognized, and that the nomeclature
system be applied prospectively to future
derivations.
The second point is that the proposed
rule might not accommodate the large
numbers of potential iPSC clones. Since
iPSCs are derived from multiple original
cells with multiple different methods, one
can obtain 100 or more iPSC clones
from a single experiment. Moreover, for
the established clones, many will be
subcloned, and each of those clones
should retain the original clone number
and a novel subclone number. Because
of widespread derivations inmany labora-
tories, we will soon have tens of thou-
sands of iPSC clones worldwide, far
exceeding numbers of ESC clones.
Therefore, the numbering system must
be large enough and scalable to accom-
modate numerous iPSC clones. On the
other hand, lengthy codes such as
the proposed 14-digit code are compli-
cated and inconvenient in a daily working
routine. For practical reasons,most scien-evier Inc.tists will avoid such codes when labeling
cell lines on cell culture dishes or cryo-
tubes. The consequence might be that
many labs rapidly adopt their own
short versions of the nomenclature, which
is counterproductive to introducing a
uniform labeling system. For that reason,
and considering the huge number of
anticipated cell lines over the next few
years, any proposed coding system
should include a segment denoting
the shortest possible unique identifier
(composed of letters and figures).
For ease of use, we also suggest that
the nomenclature also retain somemeans
of indicating species, as there is utility in
distinguishing human iPSCs from mouse
iPSCs—perhaps the green box in Figure 1
of Luong et al., 2011 should contain
species designation. The green box
might also include designations for other
types of pluripotent lines being created
(NT, parthenogenesis, EGC, EpiSC, etc.),
which don’t seem to be considered by
these authors.
Finally, the development of a nomen-
clature system should be aligned with
newly emerging stem cell registries, data-
bases, and cell banks. Centralized
storage of information, including prove-
nance, source, derivation method, char-
acterization, genetic identity, and sterility,
would facilitate research and biomedical
use of a uniformly labeled cell line
resource. Here, a key challenge to be
met is the development of common stan-
dards for the data entries and confirma-
tion of their validity.
In summary, we recommend some
modifications to the proposed rule in the
Luong et al. article. We encourage further
discussion to establish a consistent
nomenclature system for the future deri-
vation of iPSC clones, especially, but
also ESC clones. Because iPSC tech-
nology is still quite new, for the moment
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enough for the field to maintain current
clone IDs (thus allowing ‘‘self-renewal’’),
while giving us time to adopt a differenti-
ated approach for future derivations.REFERENCES
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biomaterialdiversity, theATCCrecognizes
the importance of a naming convention
that is both clearly descriptive and consis-
tently applied. We therefore agree with
and support the objective of the authors
of ‘‘A Call for Standardized Naming and
Reporting of Human ESC and iPSC Lines’’
(Luong et al., 2011). We have some addi-
tional suggestions to clarify and broaden
the naming convention.
Pluripotent stem cell lines of various
sources display significant differences in
methylation signature and/or differentia-
tion ability (Hanna et al., 2010; Bock
et al., 2011; Lister et al., 2011; Burridge
et al., 2011; Kattman et al., 2011). As
such, there is an ever-growing call for
standardization to define what ‘‘pluripo-
tent cell’’ means as a strict cell biology
definition. This definition will be more
accurately determined if we include the
character of pluripotent cells of all types.
Therefore, the naming convention should
include designations for embryonal carci-
noma cells, parthenogenic stem cells, and
epiblast stem cells in addition to the i or e
used to designate the induced or embry-
onic origin of pluripotency.
In addition, we caution against use of
the word ‘‘disease’’ in naming pluripotent
cells as this breeds ambiguity. Many
iPSCs have been derived from neonatal
foreskin fibroblasts, and thus serve as
nondiseased controls. Because of ano-
nymization of donors, it is unknown
whether they may display disease later inlife or have children who grow up to
develop a disease where the donor is
a carrier or where disease penetrance
is variable. For many multifactorial dis-
orders, disease etiology is complex;
diseases such as diabetes or cardiovas-
cular disease have divergent genetic
origins. This susceptibility to disease
may not be manifest in the iPSCs or in
any of the differentiated cell types derived
from them (Soldner et al., 2009). There-
fore, the terms ‘‘healthy’’ and ‘‘diseased’’
do not have clear meaning in the context
of pluripotent cells. After all, no pluripotent
cell donor is normal or healthy, but some-
where within a spectrum of genetic diver-
sity and susceptibility to disease. We
suggest that the specification of disease
should be replaced by a descriptor of the
known genetic mutation or lack of known
genetic mutations. Medical history of the
donor is too long to be included in the
name, and should be found in any accom-
panying cell description.
A last but practical point to be consid-
ered is that the name should be short
enough to fit clearly on the label of
a 1.5 ml cryoampule when written with an
indelible marker by a gloved hand. That
is a tall order, butwesuggest that thechar-
acter number should not be more than 10.
We would propose that the following be
key elements of the name: lab origin (two
letter code, similar to the system used to
name candidate drugs); source organ
(two letters such as ec for embryonal
carcinoma); sex (X or Y); presence orabsence of permanent genetic modifica-
tion (i for insertions, n for no insertions);
and a unique four-number code that
would be linked to a known genetic iden-
tity or subclone from a parent line.
As a member of the stem cell research
community, the ATCC expects that
pluripotent cells will continue to have
a transformative effect on the study of
human disease, the evaluation of drugs,
and the replacement of damaged tissues.
The ATCC feels that the standardization
of naming, cell definition, and cell char-
acter are all essential measures to help
realize that potential. Recognizing the
positive impact a nonprofit organization
that specializes in preserving biomaterial
diversity can have in this area, the ATCC
has established a repository exclusive to
pluripotent cells. In accordance with the
ATCC mission, this repository was de-
signed with the goal of enabling research
by providing cells that are licensed for
research use.
The cells in the ATCC repository will
meet the criteria for pluripotency estab-
lished through dialog with experts in the
field. Quality, consistency, and reliability
will be assured through the application
of rigorous QC specifications. In conjunc-
tion with this effort, the ATCC is devoting
resources to create an online database
to store and organize descriptive and
experimental data related to pluripotent
cells. The ATCCwill seek the participation
of stem cell researchers in the creation of
these tools in order to harmonize theell 8, June 3, 2011 ª2011 Elsevier Inc. 607
